Uploaded April 2026 | Updated September 2026, 2 hours ago
Supported by Astral Systems
Radioligand therapy relies heavily on a few isotopes. What alternatives could expand the toolkit, and what would it take to make them in large quantities?
Moderator: Elizabeth Sukkar, Senior research manager, policy and insights, Economist Impact
Anikitos Garofalakis, Senior medical radioisotopes advisor, OECD Nuclear Energy Association
Nadezda Gracheva, chief operating officer nuclear medicine, Swiss Rockets
Tom Wallace-Smith, co-founder and chief technology officer, Astral Systems
Richard Wahl, professor of radiology and radiation oncology, Washington University
Supported by Astral Systems
Radioligand therapy relies heavily on a few isotopes. What alternatives could expand the toolkit, and what would it take to make them in large quantities?
Moderator: Elizabeth Sukkar, Senior research manager, policy and insights, Economist Impact
Anikitos Garofalakis, Senior medical radioisotopes advisor, OECD Nuclear Energy Association
Nadezda Gracheva, chief operating officer nuclear medicine, Swiss Rockets
Tom Wallace-Smith, co-founder and chief technology officer, Astral Systems
Richard Wahl, professor of radiology and radiation oncology, Washington University
